Michal Preminger

Head of Innovation, East North America

2018 - Current

In this role, I lead the Boston innovation team to build, advance, and manage J&J's External R&D portfolio of co-investments spanning across pharmaceutical, consumer health and medical devices.  

Member Board Of Directors

2021

Member Board Of Directors

2021

Advisory Board Member

2022

LabCentral Ignite is a powerful platform that’s addressing systemic racial, gender and other underrepresentation in talent across the life sciences and the biotech industry – from labs to leadership, and from the STEM student pipeline to the entrepreneurs advancing life-changing innovations. Through a range of equity-driven programs and a powerful member network of industry partners, startups, higher education, and nonprofits, Ignite connects underrepresented students and innovators to academic, technical skills-building, mentoring, job placement, and board and leadership preparation opportunities that fuel biotech diversity and transform careers. I’m honored to be on the AdBoard alongside other amazing DEI and health equity leaders including Kenn Turner, CEO of Mass Life Science Center, Jo Vineyard, CEO at Seismic Therapeutics, The hon. Deval Patrick, former Governor of Massachusetts, and others

Advisory Board Member

2022

Member of the Scientific Advisory Board

2014

At FutuRx, Johnson & Johnson Innovation – JJDC, Takeda Pharmaceutical Company, through its venture group Takeda Ventures Inc. and OrbiMed Israel Partners teamed with the Office of the Chief Scientist of the Ministry of Economy in a national initiative to transform breakthrough discoveries into novel medicines by applying a unique structure of equally balanced partnership among its three founding organizations. FutuRx envisions its role as a catalyst for drug development by bridging the gap between concept and proof-of-concept through its dedicated system and unique structure. FutuRx management, together with its founders, will establish and fully support the companies via its in-house laboratory and management facility.

Member Board Of Directors

2017 - 2018

http://www.prnewswire.co.il/news-releases/compugen-to-present-at-two-upcoming-investor-conferences-in-june-623813913.html

Member of the Scientific Advisory Board

2007 - 2018

Prize4Life was founded in 2006 with a singular mission: to accelerate the discovery of treatments and a cure for ALS, a terminal disease whose cause has eluded scientists for over a century. Since then, we have successfully launched and awarded several prizes and programs that have taken us closer to fulfilling that mission. In late 2013, the Board of Directors and management team of Prize4Life took the decision to re-focus its activities to support a single program: the $1M Avi Kremer ALS Treatment Prize4Life. To find out more about this Prize and milestones associated with it, please click here. The rest of Prize4Life's programs, including the award winning PRO-ACT database, the ALS Prediction Algorithm Tool, and ALSGene, will be transferred to its sister organization, Prize4Life Israel, and the ALS Forum will continue as a collaborative program between the two organizations. - See more at: http://www.prize4life.org/#sthash.VclfWE5D.dpuf

Executive Director

2005 - 2018

Executive Director of the Harvard Medical School (HMS) site of Harvard Office of Technology Development (OTD) In collaboration with HMS leadership, faculty and industry/VC community, proactively generating and implementing partnership opportunities that are based on HMS research, inventions & technologies and faculty expertise, and aligned with HMS overall strategy. To enable sustained growth, executing processes for scaleup of outreach to faculty and industry, technology and market assessment, technology development, startup formation, revision of business models for partnership between industry and Harvard. Involved, with relevant experts, in intellectual property strategy, enforcement and litigation related to HMS IP portfolios. Working with faculty, the VC community, strategic partners (CROs, pharma), and business entrepreneurs to form and fund startup companies based on HMS technologies; serve as observer on some of their boards. Initiating and negotiating deals with biotech, pharmaceutical companies, research tool providers, food and cosmetics companies such as Roche, Ipsen, UCB Pharma, GlaxoSmithKline, Pfizer, Novartis, Vertex Pharmaceuticals, Danone, Estee Lauder, Unileverl, Millennium Pharmaceuticals (Takeda), Sanofi, Bristol-Myers-Squibb, Boehringer-Ingelheim, Sepracor, Genzyme, Merck & Co, Duramed Pharmaceuticals, Sirtris Pharmaceuticals (GSK), Invitrogen Corporation (Life Technologies), New England Biolabs and startup companies companies including: Genocea Biosciences, Constellation Pharmaceuticals, Selecta Biosciences, CoStim Pharmaceuticals, Insero Health, Somahlution, Mellitus, Enumeral and others.

Member of the Board of Directors

2010 - 2016

Elminda is a startup company developing a non-invasive neuro-technology for psychiatrists, neurologists and developers of neuro-psychiatric treatments to enable more informed and accurate clinical decisions. Elminda’s technology enables direct and sensitive observation of the dynamic Brain Networks Activation patterns relating to brain disorders and to the changes induced by treatment. By accurately identifying distinct diseases, disease sub-types and differential response to treatment, the technology can used for diagnostic and companion diagnostic applications, as well as as a biomarker in support of clinical development. Elminda is already generating revenue from its pharmaco-imaging business.